{"id":"oral-sitagliptin-supplementation","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Upper respiratory tract infection"},{"rate":"5-10%","effect":"Musculoskeletal pain"}]},"_chembl":{"chemblId":"CHEMBL1201174","moleculeType":"Small molecule","molecularWeight":"523.33"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This leads to increased levels of incretin hormones, which in turn stimulate the release of insulin and decrease the release of glucagon, resulting in improved glycemic control. Sitagliptin does not stimulate insulin release or increase insulin sensitivity, but rather enhances the body's natural response to elevated glucose levels.","oneSentence":"Sitagliptin works by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4), which breaks down incretin hormones.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:24:43.034Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT06115460","phase":"PHASE3","title":"The Impact of Sitagliptin as an Add on Therapy With Closed Loop Control in Adolescents With Diabetic Nephropathy","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-03-01","conditions":"Type 1 Diabetic Nephropathy","enrollment":46}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"oral sitagliptin supplementation","genericName":"oral sitagliptin supplementation","companyName":"Ain Shams University","companyId":"ain-shams-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sitagliptin works by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4), which breaks down incretin hormones. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}